Mixed-audience model: traffic, repeat visits, engagement, countries and growth, with assumed paying share and monthly revenue per account.
Estimated active users × assumed paying share × estimated monthly revenue per customer. We distinguish B2B, B2C and creator tools, and use comparable revenue when available. These are model assumptions, not measured sales.
Indicative range $125–$5k
Monthly visits
5.3k-33,4%
Chart unavailable
Estimated visitsAverage duration0m 24s
Audience
Share of monthly visits
Map unavailable. Country shares are listed alongside.
ALIS Medtelligent receives an estimated 5,302 visits in September 2026.
This represents a change of -33.4% compared with August 2026 (7,966 visits).
These are estimated visits, not unique users or paying customers. Traffic growth does not establish sales growth.
Monthly traffic history
ALIS Medtelligent — estimated visits
Month
Visits
12,975
7,966
5,302
Confidence in the figures
Revenue and sources
ALIS Medtelligent has an estimated monthly revenue of $790. This is an estimate, not company-reported revenue or payment-verified MRR.The model uses available product, traffic and comparable SaaS signals; its assumptions remain uncertain.
Geography
Where do visitors come from?
The leading countries for visits to ALIS Medtelligent are: United States (100.0%). These shares describe website traffic, not the location of paying customers.
Distribution
Acquisition channels
The recorded channels include: Direct (39.2%), Search (32.1%), Referrals (10.5%).Coverage may be partial: a missing value does not establish that a channel is unused. These visits do not measure conversions or advertising returns.
The YouTube and Meta Ads sections let you explore collected mentions and creatives. Access depends on your account and subscription.
Similar SaaS and alternatives to ALIS Medtelligent
The selection of SaaS to compare includes Tikr.Similarity is assessed from available descriptions, categories and use cases. It does not guarantee equivalent features or pricing.
Answers based on the data available in this profile.
How much traffic does ALIS Medtelligent get?+
ALIS Medtelligent receives an estimated 5,302 visits in September 2026. These are estimated visits, not unique users or paying customers. Traffic growth does not establish sales growth.
Are the revenue figures for ALIS Medtelligent verified?+
ALIS Medtelligent has an estimated monthly revenue of $790. This is an estimate, not company-reported revenue or payment-verified MRR.The model uses available product, traffic and comparable SaaS signals; its assumptions remain uncertain.
Is traffic to ALIS Medtelligent growing?+
This represents a change of -33.4% compared with August 2026 (7,966 visits). These are estimated visits, not unique users or paying customers. Traffic growth does not establish sales growth.
Where do visitors to ALIS Medtelligent come from?+
The leading countries for visits to ALIS Medtelligent are: United States (100.0%). These shares describe website traffic, not the location of paying customers.
Which SaaS can I compare with ALIS Medtelligent?+
The selection of SaaS to compare includes Tikr.Similarity is assessed from available descriptions, categories and use cases. It does not guarantee equivalent features or pricing.
How recent is this data?+
The catalog data was last updated on October 17, 2026.The latest available traffic month is September 2026.Traffic periods, collection dates and revenue source dates can differ.
SaaS similar to ALIS Medtelligent
Matched by what the product does. Traffic only breaks ties.
Product similarity
SaaS informationMonthly trafficMonthly revenue
01
T TikrRelated use case
tikr.com Similar product features832.8k
visits / month
−6,3%US40,3%ES17,4%KR9,1%$84.4k
Countries reached
Public reach reported by Meta
CountryReachShare
Other countries
Share calculated from Meta's reported reach breakdown. Spend by country is not published.
Verified MRR
Source: TrustMRR
How is it estimated?
This is a revenue estimate, not payment-verified MRR.
This is an order-of-magnitude estimate, not an accounting figure.